Chamberlain, Philip P.

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 863

A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 701

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 531

Development of targeted protein degradation therapeutics

Chamberlain, P. P., & Hamann, L. G. (2019) · Nature Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 489

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology

Protein Degradation and InhibitorsPharmacological Effects and Toxicity Studies

Cited by 338

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

Matyskiela, M. E., Zhang, W., Man, H.-W., Muller, G., Khambatta, G., Baculi, F., Hickman, M., LeBrun, L., Pagarigan, B., Carmel, G., et al. (2018) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 309

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Surka, C., Jin, L., Mbong, N., Lu, C.-C., Jang, I. S., Rychak, E., Mendy, D., Clayton, T., Tindall, E., Hsu, C., et al. (2021) · Blood

Protein Degradation and InhibitorsAcute Myeloid Leukemia Research

Cited by 229

Molecular glue CELMoD compounds are regulators of cereblon conformation

Watson, E. R., Novick, S., Matyskiela, M. E., Chamberlain, P. P., H. de la Peña, A., Zhu, J., Tran, E., Griffin, P. R., Wertz, I. E., & Lander, G. C. (2022) · Science

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 208

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Gooding, S., Ansari-Pour, N., Towfic, F., Ortiz Estévez, M., Chamberlain, P. P., Tsai, K.-T., Flynt, E., Hirst, M., Rozelle, D., Dhiman, P., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 172

Cereblon modulators: Low molecular weight inducers of protein degradation

Chamberlain, P. P., & Cathers, B. E. (2019) · Drug Discovery Today: Technologies

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 106

Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex

Matyskiela, M. E., Clayton, T., Zheng, X., Mayne, C., Tran, E., Carpenter, A., Pagarigan, B., McDonald, J., Rolfe, M., Hamann, L. G., et al. (2020) · Nature Structural & Molecular Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 103

UBE2G1 governs the destruction of cereblon neomorphic substrates

Lu, G., Weng, S., Matyskiela, M., Zheng, X., Fang, W., Wood, S., Surka, C., Mizukoshi, R., Lu, C.-C., Mendy, D., et al. (2018) · eLife

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 78